Tenax Therapeutics (TENX) Accumulated Expenses (2011 - 2026)

Tenax Therapeutics (TENX) has 15 years of Accumulated Expenses data on file, last reported at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 130.36% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (up 130.36% YoY), and the FY2025 full-year result was $1.1 million, down 27.41% from the prior year.
• Accumulated Expenses grew to $2.1 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $2.1 million in Q1 2026 to a low of $47416.0 in Q3 2023.
• A 5-year average of $787323.1 and a median of $775045.0 in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 83.2% in 2022 and surged 1961.64% in 2024, its largest moves.
• Tracing TENX's Accumulated Expenses over 5 years: stood at $775045.0 in 2022, then soared by 30.7% to $1.0 million in 2023, then surged by 51.63% to $1.5 million in 2024, then fell by 27.41% to $1.1 million in 2025, then soared by 91.93% to $2.1 million in 2026.
• Business Quant data shows TENX's Accumulated Expenses at $2.1 million in Q1 2026, $1.1 million in Q4 2025, and $991000.0 in Q3 2025.